[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632708":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":61,"collaborators":20,"id":63,"slug":20,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":20,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":20,"enrollmentInfo":71,"targetDuration":20,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":91,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},{"fullName":5,"class":6},"Exscientia AI Limited","INDUSTRY",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"EXS74539","EXPERIMENTAL",[12],"Drug: EXS74539",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"DRUG","Oral administration",[9],[19],"REC-4539",null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Exscientia AI Ltd.","CONTACT","385-374-1724","clinicaltrials@recursion.com",[28,41,51],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":20},"Start Lacn","RECRUITING","Los Angeles","California","90025","United States",{"type":36,"coordinates":37},"Point",[38,39],-118.24368,34.05223,{"lat":39,"lon":38},{"facility":42,"status":30,"city":43,"state":44,"zip":45,"country":34,"cosmosGeoPoint":46,"geoPoint":50,"contacts":20},"START Dallas","Fort Worth","Texas","76104",{"type":36,"coordinates":47},[48,49],-97.32085,32.72541,{"lat":49,"lon":48},{"facility":52,"status":30,"city":53,"state":54,"zip":55,"country":34,"cosmosGeoPoint":56,"geoPoint":60,"contacts":20},"START Mountain Region","West Valley City","Utah","84119",{"type":36,"coordinates":57},[58,59],-112.00105,40.69161,{"lat":59,"lon":58},{"type":62,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100632708",false,"NCT07517198","Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors","A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Efficacy of EXS74539 as Monotherapy in Participants With Select Solid Tumors","Key Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Histologically confirmed diagnosis of the following solid tumors:\n\n  * SCLC\n  * High grade neuroendocrine or small cell carcinomas of non-lung origin\n  * Non-small cell lung cancer \\[NSCLC\\]\n  * Prostate cancer\n  * Ovarian cancer\n  * Renal carcinoma \\[clear and non-clear cell\\]\n  * Head and neck squamous cell carcinoma\n  * Hepatic cancer\n  * Gastric cancer\n  * Triple-negative breast cancer \\[TNBC\\]\n* Participant disease should have progressed, relapsed or the participants should have been intolerant to at least one prior standard systemic therapy for their respective underlying malignancy.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n\nKey Exclusion Criteria:\n\n* Any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study.\n* Symptomatic brain metastases, leptomeningeal metastases, or spinal cord compression due to disease. Participants with brain metastases must be clinically stable and off corticosteroids and anticonvulsants for ≥1 month prior to study treatment and not require any specific intervention for brain metastases.\n* Active and clinically significant infection requiring systemic antibacterial, antiviral, or antifungal therapy \\\u003C7 days of the first scheduled dose of the study treatment.\n* Significant cardiac abnormalities.\n* Major surgery within 28 days prior to the start of study treatment.\n\nNote: Other protocol-defined inclusion and exclusion criteria may apply.","ALL","18 Years",{"count":72,"type":73},40,"ESTIMATED","INTERVENTIONAL",[76],"PHASE1","The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.",[79,80,81,82,83,84,85,86,87,88,89,90],"Solid Tumor","Small Cell Lung Cancer (SCLC)","High Grade Neuroendocrine Cancer","Small Cell Carcinomas of Non-lung Origin","Non-small Cell Lung Cancer (NSCLC)","Prostate Cancer","Ovarian Cancer","Renal Carcinoma (Clear and Non-clear Cell)","Head and Neck Squamous Cell Carcinoma (HNSCC)","Hepatic Cancer","Gastric Cancer","Triple-negative Breast Cancer (TNBC)",[92,80,93,94,95,96,97,98,99,100,101,102,103,9,19],"Solid Tumors","High grade neuroendocrine cancer","Small cell carcinomas of non-lung origin","Non-small cell lung cancer (NSCLC)","Prostate cancer","Ovarian cancer","Renal carcinoma (clear and non-clear cell)","Head and neck squamous cell carcinoma (HNSCC)","Hepatic cancer","Gastric cancer","Triple-negative breast cancer (TNBC)","LSD1 inhibitor","2026-06-09",{"date":106,"type":107},"2026-06-10","ACTUAL",{"date":109,"type":107},"2026-04-13",{"date":111,"type":73},"2029-03",{"name":113,"class":6},"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",3]